AstraZeneca Ends European Licensing Pact With Valeant

The British pharmaceutical giant says the Canadian drugmaker will continue to lead development and marketing of psoriasis drug brodalumab in the U.S.

from WSJ.com: US Business http://ift.tt/297q4qz
via IFTTT